Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines

Journal of Lower Genital Tract Disease

Volumn 21, Issue 4, 2017, Pages 261-267

  Demarco, Maria ^a   Lorey, Thomas S ^b   Fetterman, Barbara ^b   Cheung, Li C ^a   Guido, Richard S ^c   Wentzensen, Nicolas ^a   Kinney, Walter K ^b   Poitras, Nancy E ^b   Befano, Brian ^d   Castle, Philip E ^e   Schiffman, Mark ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

cervical cancer; management guidelines; screening

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; CYTOLOGY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOW RISK PATIENT; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PREDICTION; PREVALENCE; RISK ASSESSMENT; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; TIME TO TREATMENT; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PREDICTIVE VALUE; PROCEDURES; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; AGED; CYTOLOGICAL TECHNIQUES; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

EID: 85040791600     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0000000000000343     Document Type: Article

References (22)

1. Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013; 121: 829-46.
2. Schiffman M, Wentzensen N, Khan MJ, et al. Preparing for the next round of asccp-sponsored cervical screening and management guidelines. J Low Genit Tract Dis 2017; 21: 87-90.
3. Castle PE, KinneyWK, Cheung LC, et al. Why does cervical cancer occur in a state-of-the-art screening program? Gynecol Oncol 2017; pii: S0090-8258: 30898-3.
4. Castle PE, Solomon D, Wheeler CM, et al. Human papillomavirus genotype specificity of hybrid capture 2. J ClinMicrobiol 2008; 46: 2595-604.
5. Cheung LC, Pan Q, Hyun N, et al. Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records. [published online ahead of print June 28, 2017]. Stat Med 2017. doi: 10. 1002/sim. 7380.
6. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis 2013; 17(5 Suppl 1): S56-63.
7. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results. J Low Genit Tract Dis 2013; 17(5 Suppl 1): S50-5.
8. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results. J Low Genit Tract Dis 2013; 17(5 Suppl 1): S43-9.
9. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results. J Low Genit Tract Dis 2013; 17(5 Suppl 1): S36-42.
10. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPVand Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 2013; 17(5 Suppl 1): S28-35.
11. Wentzensen N, Walker JL, Gold MA, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol 2015; 33: 83-9.
12. Wentzensen N, Schiffman M, Silver MI, et al. ASCCP Colposcopy Standards: risk-based colposcopy practice. J Low Genit Tract Dis 2017; 21: 230-4.
13. KinneyW, Wright TC, Dinkelspiel HE, et al. Increased cervical cancer risk associated with screening at longer intervals. Obstet Gynecol 2015; 125: 311-5.
14. Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst 2014; 106: 1-4.
15. Arbyn M, Buntinx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004; 96: 280-93.
16. Sherman ME, Castle PE, Solomon D. Cervical cytology of atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion (ASC-H): characteristics and histologic outcomes. Cancer 2006; 108: 298-305.
17. Carreon JD, Sherman ME, Guillén D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological reviewof population-based cervical samples. Int J Gynecol Pathol 2007; 26: 441-6.
18. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSILTriage Study. JAMA 2001; 285: 1500-5.
19. Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115, 789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012; 131: 2349-59.
20. Gage JC, Hunt WC, Schiffman M, et al. Similar risk patterns after cervical screening in two largeU. S. populations: implications for clinical guidelines. Obstet Gynecol 2016; 128: 1248-57.
21. Katki HA, Gage JC, Schiffman M, et al. Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis ofCIN1 or less. J Low Genit Tract Dis 2013; 17(5 suppl 1): S69-77.
22. Katki HA, Schiffman M, Castle PE, et al. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPVand Pap cotesting in posttreatment management. J Low Genit Tract Dis 2013; 17(5 Suppl 1): S78-84.